Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
podcast with Tim Boreham
podcast with Tim Boreham

Melbourne, Oct 18, 2019 AEST (ABN Newswire) - Anatara Lifesciences (googlechartASX:ANR) CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".

Anatara Lifesciences: Standing out in the gut health market, solving scours in livestock and the future of antibiotics in the food chain

In the interview, Steve discusses:

- Anatara's journey to today and its dual opportunities in human and animal gut health

- The significant unmet need for complementary medicines in the treatment of irritable bowel syndrome and inflammatory bowel disease

- How Anatara's Gastrointestinal ReProgramming (GaRP) dietary supplement unique approach addresses all three significant factors in chronic bowel conditions - microbiome dysbiosis, inflammation and mucosal damage

- Recent successful completion of GaRP's preclinical program, with statistically significant efficacy data from its in vivo animal studies and further positive in vitro proof of concept data

- The upcoming human clinical trial for GaRP and in parallel, the preparation of a licencing package to approach potential partner companies in 2020

- The next step's for partnering the Company's anti-diarrhoeal product, Detach(r), in global markets and other livestock species

- Antimicrobial resistance is one of the greatest threats to mankind and how Detach(r) will help reduce in the use of antibiotics in livestock

Listen to the podcast interview please visit:
https://www.abnnewswire.net/lnk/HT7L087J


About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

https://twitter.com/anataraanr https://www.facebook.com/profile.php?id=61550997392627 https://www.linkedin.com/company/anatara-lifesciences-ltd abnnewswire.com 


Contact

Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com


ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 4) (Last 30 Days: 32) (Since Published: 3423)